G
Guangzhou Kang Liming Biotechnology
The leading advanced bio-tech enterprise in IVD and POCT industry
About Guangzhou Kang Liming Biotechnology
Creative Bio is a biotechnology company specializing in early cancer screening and advanced genomic research. The company operates in the healthcare and life sciences market, providing cutting-edge solutions for both clinical and research applications. Creative Bio serves a diverse clientele, including hospitals, research institutions, and academic organizations. The company's business model revolves around the development and commercialization of highly sensitive diagnostic tests and automated laboratory equipment. Revenue is generated through the sale of diagnostic kits, laboratory instruments, and related services. Key products include the Human SDC2 Genomethylation test box and fully automated sample processors, which feature real-time display, data recording, UV light disinfection, and user-friendly touch screen interfaces. Creative Bio's innovative technologies enable accurate and efficient detection of cancer markers, contributing to early diagnosis and improved patient outcomes. The company also engages in scientific research projects, publishes academic journals, and participates in industry events to stay at the forefront of technological advancements.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Oct 2021 | $77M | $413M | Alibaba · IDG Capital · Cornerstone Capital · Henglu Assets | — |
| SERIES COther financing | Sep 2020 | $83M | $330M | IDG Capital · CDH Investments · Qingsong Fund · Oceanpine Capital | — |
Growth signals
Latest recorded traffic for Guangzhou Kang Liming Biotechnology is 940 monthly website visits, down 55.2% over the last three months. Guangzhou Kang Liming Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Guangzhou Kang Liming Biotechnology in the Guangzhou ecosystem
The Guangzhou Kang Liming Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
CD Capital
IDG Capital
CDH Investments
Series B and later8 investors entered at this stage
- QFQingsong Fund
Oceanpine Capital- JIJundu investment
Alibaba- CCCornerstone Capital
- HAHenglu Assets
- AIABC International
- HFHuaxing Fund
Other known investors2 additional known investors
Mayo Clinic College of Medicine and Science
Sun Yat-sen University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guangzhou Kang Liming Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guangzhou Kang Liming Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







